Form 4: Quest Diagnostics Executive Kuppusamy Reports Stock Transactions
SEC Form 4 Filing
Karthik Kuppusamy, SVP at Quest Diagnostics, reports acquisition and disposition of company stock related to a performance share award.
Summary
- Karthik Kuppusamy, a Senior Vice President at Quest Diagnostics, filed a Form 4 detailing changes in beneficial ownership of the company's stock.
- On February 23, 2024, Kuppusamy acquired 2,039 shares of common stock at $125.02 per share as settlement of a performance share award dated February 18, 2021.
- On the same day, Kuppusamy disposed of 619 shares at $125.02 per share to cover tax withholding obligations related to the settlement of the performance share award.
- Following these transactions, Kuppusamy directly owns 15,397 shares of common stock.
- Kuppusamy also indirectly owns 358 shares through a trust and 1,513 shares through the company's 401(k) plan.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity related to executive compensation and tax obligations.
Stakeholder Impact
- The transactions have a minor impact on shareholders as they reflect routine executive compensation adjustments.
Key Dates
| Date | Description |
|---|---|
| February 18, 2021 | Date of the performance share award. |
| February 23, 2024 | Date of stock acquisition and disposition. |
| February 27, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.